Zimbabwe has rejected a substantial American health deal worth $367m (£272m) over five years due to Washington's request for sensitive data.
This move came to light following a government memo dated December was leaked, which showed President Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official spokesperson has since stated that the US was seeking genetic material for research and commercial gain while was not willing to share the resulting advantages from any future medical innovations.
"We will now turn to the difficult and regrettable task of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided over $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has appealed for more dialogue to reach a agreement agreeable to all parties so the country's vital HIV treatment initiative can be sustained.
Wider Background
This rejection follows a comparable situation in neighbouring Kenya, where a high court blocked a similar health funding agreement following legal challenges were raised about the safety of citizens' health data.
Since resuming the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump argued its spending was "inefficient" and his administration was seeking government-to-government agreements to boost openness and accountability.
As per statements, 16 nations in Africa have to date signed these new agreements, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation could have provided extraordinary advantages for Zimbabwean communities, especially the 1.2 million currently on HIV treatment via US-supported initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, with no equivalent assurance of access to any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," he stated.
"In essence, our nation would provide the raw materials for medical research without any assurance that the end products would be available to our citizens should a future disease outbreak arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its push of one-on-one health agreements were upending systems already set up via the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing framework designed to manage future global health emergencies.
"This system is designed to ensure that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how future collaboration could be structured in a way that respects the independence and interests of both nations."
Health Experts Response
Medical experts expressed it acknowledged the government's concerns, but suggested that negotiations should continue since a large portion of the nation's HIV programmes relied on foreign aid.
"Where technical issues arise, including those relating to data governance or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," the group added.
The halted deal highlights the ongoing debate between receiving vital international aid and protecting national sovereignty in an ever more interconnected world.